Investigational drug · Phase 2
IMG-007
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
6
Any phase or sponsor naming "IMG-007"
First trial start
2023
Sep 25, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IMG-007", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
- Atopic Dermatitis Eczema
- Eczema
- Alopecia Areata (AA)
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Alopecia areata · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "IMG-007" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic DermatitisPivotal-lookingRecruiting
Inmagene LLCIndustry
NCT07037901 · 405 participants (planned) · Start Jun 17, 2025 · Primary completion Dec 2027
Drug: IMG-007; Placebo · For: Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema
Sites: Lancaster, California; Los Angeles, California; Ocala, Florida · 33 sites in all
- Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic DermatitisEnrolling by invitation
Inmagene LLCIndustry
NCT07734415 · 400 participants (planned) · Start Jun 5, 2026 · Primary completion Mar 2028
Drug: IMG-007 · For: Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema
Sites: Lancaster, California; Los Angeles, California; Ocala, Florida · 23 sites in all
Inmagene LLCIndustry
NCT05353972 · 44 participants · Start Jul 5, 2022 · Primary completion May 31, 2023
Drug: IMG-007 or placebo · For: Healthy Participants
Sites: Nedlands, Australia
Inmagene LLCIndustry
NCT06060977 · 29 participants · Start Sep 25, 2023 · Primary completion Jan 14, 2025
Drug: IMG-007 · For: Alopecia Areata (AA)
Sites: Rogers, Arkansas; Lomita, California; Tampa, Florida · 17 sites in all
Inmagene LLCIndustry
NCT06304740 · 16 participants · Start Mar 6, 2024 · Primary completion Aug 28, 2024
Drug: IMG-007; Placebo · For: Healthy Volunteers
Sites: Perth, Australia
Inmagene LLCIndustry
NCT05984784 · 13 participants · Start Aug 9, 2023 · Primary completion Apr 26, 2024
Drug: Placebo; IMG-007 · For: Atopic Dermatitis; Moderate-to-severe Atopic Dermatitis; AD
Sites: Northridge, California; Valencia, California; Miami, Florida · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The Role of OX40 Pathway Inhibition as a New Therapeutic Strategy for Atopic Dermatitis.
Oliveira Dos Santos D, Mohamed A, Mohamed A, et al. · BioDrugs 2026
- Extended Half-life Antibodies: A Narrative Review of a New Approach in the Management of Atopic Dermatitis.
Yilmaz O, Torres T · Dermatol Ther (Heidelb) 2024
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.